LENZ Therapeutics, Inc. LENZ 深 滬
等待開盤 08-10 09:30:00 美东时间
5.36
+0.140
+2.68%
華盛通- 最 高5.42
- 今 開5.29
- 成交量 45.30万股
- 最 低 5.21
- 昨 收 5.22
- 總市值 1.68亿
- 52周最高 50.40
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 4.68
- 委 比 -10.57%
- 總股本 3135.44万
- 歷史最高 230.79
- 量 比 0.53
- 振 幅 4.02%
- 歷史最低 3.92
- 每 手 1
- 風險率 13.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.
07-07 18:27
LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that VIZZ is now available through a convenient telehealth p...
07-06 20:20
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics, Inc. (NASDAQ:LENZ) on Wednesday announced an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. The agreement marks LENZ’s latest effort to expand the commercial reach of its recently approved eye drop therapy beyond the U.S. market. Read Als...
06-25 01:41
LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand. LENZ Therapeutics is a pharmaceuti...
06-24 20:32
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12
Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.
05-12 18:23
LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 149.06 percent decrease over losses of $(0.53) per share
05-12 04:07
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
